PE Tech Report


Like this article?

Sign up to our free newsletter

iOmx Therapeutics raises EUR40 million in Series A round

iOmx Therapeutics has closed a Series A financing round totalling EUR40 million, co-led by MPM Capital and Sofinnova Partners.

Wellington Partners and Merck Ventures also invested.
iOmx focuses on the development of cancer therapeutics addressing next-generation immune checkpoints. By systematically screening human tumour cells, the company has already identified a number of new targets and analysed their mode of action.
The proceeds of the financing round will be used to advance several proprietary product candidates up to initial clinical proof-of-concept.
iOmx was founded based on work from the laboratory of oncology expert and co-founder Philipp Beckhove, previously at the German Cancer Research Center, Heidelberg, and now at the RCI Regensburg Center for Interventional Immunology.
The company’s screening platform was developed by co-founder Nisit Khandelwal, senior vice president of research. Additional co-founders include biotech executives and internationally renowned cancer specialists Patrick Baeuerle, Elmar Maier (CBO), and Sebastian Meier-Ewert (CEO).   
"The development of checkpoint inhibitors represents a major advance in the treatment of certain cancers. However, despite some truly transformative successes, to date only a minority of patients benefit from existing treatment options. We aim to bring the advances in immuno-oncology to a greater proportion of cancer patients," says Meier-Ewert. "Therefore, we are proud to have attracted such an outstanding international investor base. The round was significantly oversubscribed, highlighting the expectation that immune checkpoint-based cancer therapeutics have great potential for changing the oncology landscape – and iOmx is excellently positioned to play a leading role in this field."
"We are thrilled to back iOmx, together with such a high profile investor syndicate. The company combines all the key features we are looking for when investing: an exceptional management team, world class science, and a market breaking technology platform that has the potential to build a strong pipeline of proprietary and more efficacious cancer therapeutics," says Henrijette Richter, chairwoman of iOmx’s board of directors and partner at Sofinnova Partners.

Like this article? Sign up to our free newsletter